试图改善脂性药物的溶解性和生物可用性:专注于芬雷丁尼德
Silvana Alfei1, Guendalina Zuccari2
1Department of Pharmacy, University of Genoa, Viale Cembrano 4, 16148 Genoa, Italy.
Pharmaceutics
|May 25, 2024
概括
雷丁胺 (4-HPR) 显示出对抗癌症的希望,但其生物利用性较差. 本综述审查了改善雷丁胺药物输送和疗效的策略,以获得更好的临床结果.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物开发 药物开发
- 癌症治疗方法 癌症治疗方法
背景情况:
- 芬雷丁胺 (4-HPR) 是第二代视网类药物,在体外表现出强大的抗癌活性.
- 芬雷丁胺的临床试验因口服生物可用性低而受到阻碍,导致血中药物度不足和有效性变化.
- 较差的水溶性和高的肝脏第一通代谢有助于瑞的生物制药挑战.
研究的目的:
- 审查和比较旨在提高芬雷丁尼德 (4-HPR) 生物可用性的各种方法.
- 评估不同雷丁尼德输送策略的临床前和临床早期结果.
- 建议未来的研究方向,以优化芬雷丁尼德的治疗潜力.
主要方法:
- 对调查雷丁胺生物可用性增强的研究的文献综述.
- 来自临床前和临床早期试验的数据的比较分析.
- 评估药物输送系统和雷丁尼德的配方策略.
主要成果:
- 已经探索了多种策略来改善芬雷丁胺的生物可用性,显示血水平增加和毒性降低.
- 尽管增强了交付,在许多方法中观察到适度的抗瘤疗效.
- 在实现雷丁胺的最佳治疗度和临床疗效方面,仍然存在重大挑战.
结论:
- 提高芬雷丁胺 (4-HPR) 的生物可用性对于其临床进展至关重要.
- 需要进一步的研究来克服现有的局限性,并实现雷丁胺的全部治疗潜力.
- 对配方策略的全面理解对于成功开发芬雷丁胺药物至关重要.
关键词:
4-HPR口服配方是一种口服配方.4-HPR亲肠道配方的使用方法全转化网红酸 (ATRA) 的使用.芬雷丁化物 (4-HPR) 的使用脂友性药物药物 脂友性药物低生物可用性 低生物可用性自然的视网类药物.临床前和临床试验.雷丁醇是一种可靠的药物.更多相关视频
相关概念视频
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
198
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
198
Factors Affecting Dissolution: Particle Size and Effective Surface Area
807
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
807
Factors Influencing Drug Absorption: Drug Dissolution
467
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
467
Factors Influencing Drug Absorption: Physicochemical Parameters
258
The physicochemical characteristics of drugs play a crucial role in formulating stable and bioavailable drug products. The solubility of a drug, governed by the varying pH along the GI tract and its dissociation constant (pKa), is pivotal in determining its ionization state and absorption rate. Notably, weak acids and bases remain unionized and are absorbed more rapidly.
Enhanced drug absorption can be achieved by reducing particle sizes and increasing surface areas, thereby facilitating...
Enhanced drug absorption can be achieved by reducing particle sizes and increasing surface areas, thereby facilitating...
258
Factors Influencing Bioavailability: First-Pass Elimination
6.3K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
6.3K


